Method for predicting therapeutic effect on chronic hepatitis c

A method for predicting therapeutic effect of combination therapy with peginterferon and ribavirin in chronic hepatitis C therapy, comprising:

• a step of detecting a drug-sensitivity marker in a biological sample;
• and
• a step of evaluating drug sensitivity of the biological sample on the basis of an expression level of the drug-sensitivity marker, wherein
• the biological sample is a cell or tissue derived from liver, and
• the drug-sensitivity marker comprises at least one microRNA selected from the group consisting of miR-18a (SEQ ID NO:
• 1), miR-145 (SEQ ID NO:
• 2), miR-34b (SEQ ID NO:
• 3), miR-331 (SEQ ID NO:
• 4), let-7d (SEQ ID NO:
• 5), miR-200a (SEQ ID NO:
• 6), miR-200b (SEQ ID NO:
• 7), miR-652 (SEQ ID NO:
• 8), miR-132 (SEQ ID NO:
• 9), miR-143 (SEQ ID NO:
• 10), miR-425-5p (SEQ ID NO:
• 11), miR-185 (SEQ ID NO:
• 12), miR-141 (SEQ ID NO:
• 13), miR-200c (SEQ ID NO:
• 14), miR-195 (SEQ ID NO:
• 15), miR-411 (SEQ ID NO:
• 16), miR-10a (SEQ ID NO:
• 17), miR-345 (SEQ ID NO:
• 18), miR-214 (SEQ ID NO:
• 19), miR10b (SEQ ID NO:
• 20), miR-377 (SEQ ID NO:
• 21), let-7b (SEQ ID NO:
• 22), miR-182 (SEQ ID NO:
• 23), miR-429 (SEQ ID NO:
• 24), miR-107 (SEQ ID NO:
• 25), miR-127 (SEQ ID NO:
• 26), miR-500 (SEQ ID NO:
• 27), miR-376a (SEQ ID NO:
• 28), miR-199a* (SEQ ID NO:
• 29), miR-218 (SEQ ID NO:
• 30), miR-125a (SEQ ID NO:
• 31), miR-106b (SEQ ID NO:
• 32), miR-199a (SEQ ID NO:
• 33), miR-27b (SEQ ID NO:
• 34), miR-422b (SEQ ID NO:
• 35), miR-122a (SEQ ID NO:
• 36), and miR-23b (SEQ ID NO:
• 37).